Phenylacetate inhibits growth and vascular endothelial growth factor secretion in human thyroid carcinoma cells and modulates their differentiated function

Journal of Clinical Endocrinology and Metabolism

Volumn 84, Issue 8, 1999, Pages 2840-2847

  Kebebew, Electron ^a   Wong, Mariwil G ^a   Siperstein, Allan E ^a   Duh, Quan Yang ^b   Clark, Orlo H ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b SAN FRANCISCO VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PHENYLACETIC ACID; RADIOACTIVE IODINE; THYROGLOBULIN; THYROTROPIN; VASCULOTROPIN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL DIFFERENTIATION; CELL LINE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOSTASIS; FOLLICULAR CARCINOMA; GENE EXPRESSION REGULATION; GROWTH INHIBITION; HORMONE RELEASE; HUMAN; HUMAN CELL; MITOSIS INHIBITION; PRIORITY JOURNAL; PROTEIN SECRETION; THYROID CARCINOMA; VASCULAR ENDOTHELIUM;

EID: 0033345443     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jc.84.8.2840     Document Type: Article

References (49)

1. Thyroid cancer: A lethal endocrine neoplasm
2. Prognostic factors in thyroid carcinoma
3. Well-differentiated thyroid cancer
4. Surgical reintervention for differentiated thyroid carcinoma
5. Fatal thyroid carcinoma. Anaplastic transformation of adenocarcinoma
6. Quantification of thyroglobulin messenger RNA by in situ hybridization in differentiated thyroid cancers. Difference between well-differentiated and moderately differentiated histologic types
7. The mRNA levels of thyrotropin receptor, thyroglobulin and thyroid peroxidase in neoplastic human thyroid tissues
8. Expression of thyrotropin receptor gene in thyroid carcinoma is associated with a good prognosis
9. Tamoxifen inhibits growth, migration, and invasion of human follicular and papillary thyroid cancer cells in vitro and in vivo
10. Effects of 13-cis-retinoic acid on growth and differentiation of human follicular carcinoma cells in vitro
11. Redifferentiation therapy with retinoids: Therapeutic option for advanced follicular and papillary thyroid carcinoma
12. Somatostatin analog octreotide inhibits the growth of differentiated thyroid cancer cells in vitro, but not in vivo
13. Octreotide therapy in advanced thyroid cancer
14. Phenylacetate and phenylbutyrate as novel, nontoxic differentiation inducers
15. The conjugation of phenylacetic acid in man, subhuman primates and some non-primate species
16. Treatment of episodic hyperammonemia in children with inborn errors of urea synthesis
17. A new therapy for portal systemic encephalopathy
18. Hyperammonemic encephalopathy after chemotherapy. Survival after treatment with sodium benzoate and sodium phenylacetate
19. Phase I study of phenylacetate administered twice daily to patients with cancer
20. A Phase I and pharmacokinetic study of intravenous phenylacetate in patients with cancer
21. Growth regulation of normal thyroids and thyroid tumors in man
22. Establishment of a highly differentiated thyroid cancer cell line of Hurthle cell origin
23. Culture of hormone-dependent functional epithelial cells from rat thyroids
24. Biphasic effects of thyrotropin on invasion and growth of papillary and follicular thyroid cancer in vitro
25. Sodium phenylacetate induces growth inhibition and Bcl-2 down-regulation and apoptosis in MCF7ras cells in vitro and In nude mice
26. Chemotherapy in metastatic nonanaplastic thyroid cancer: Experience at the Institut Gustave-Roussy
27. Selective growth arrest and phenotypic reversion of prostate cancer cells in vitro by nontoxic pharmacological concentrations of phenylacetate
28. Differentiation of cultured human melanoma cells induced by the aromatic fatty acids phenylacetate and phenylbutyrate
29. Induction of myogenic differentiation in a human rhabdomyosarcoma cell line by phenylacetate
30. Tumor growth inhibition, apoptosis, and Bcl-2 down-regulation of MCF-7ras tumors by sodium phenylacetate and tamoxifen combination
31. Phenylacetate inhibits isoprenoid biosynthesis and suppresses growth of human pancreatic carcinoma
32. Effects of phenylacetate on cells from patients with B-chronic lymphocytic leukemia
33. Growth inhibitory effects of sodium phenylacetate (NSC 3039) on ovarian carcinoma cells in vitro
34. Inhibition of proliferation and induction of differentiation in medulloblastoma- and astrocytoma-derived cell lines with phenylacetate
35. Regulation of the mevalonate pathway. Nature
36. Up-regulation and functional role of p21(Waf1/Cip1) during growth arrest of human breast carcinoma MCF-7 cells by phenylacetate
37. Activation of a human peroxisome proliferator-activated receptor by the antitumor agent phenylacetate and its analogs
38. Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators
39. A novel orphan receptor specific for a subset of thyroid hormone-responsive elements and its interaction with the retinoid/thyroid hormone receptor sub-family
40. The essentials of DNA methylation
41. Thyroid stimulating hormone promotes the secretion of vascular endothelial growth factor in thyroid cancer cell lines
42. Thyroid-stimulating hormone inhibits Fas antigen-mediated apoptosis of human thyrocytes in vitro
43. Elevated serum thyroglobulin. A marker of metastases in differentiated thyroid carcinomas
44. Retinoic acid increases sodium/iodide symporter mRNA levels in human thyroid cancer cell lines and suppresses expression of functional symporter in nontransformed FRTL-5 rat thyroid cells
45. Phenylacetate synergizes with retinoic acid in inducing the differentiation of human neuroblastoma cells
46. Glycosylation is essential for efficient secretion but not for permeability-enhancing activity of vascular permeability factor (vascular endothelial growth factor)
47. Vascular endothelial growth factor expression is higher in differentiated thyroid cancer than in normal or benign thyroid